Skip to main content
SpringerLink
Log in

Prostate: High-Dose Rate Brachytherapy in the Treatment of Clinically Organ-Confined Prostate Cancer

  • Chapter
  • First Online:
Brachytherapy

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 1334 Accesses

Abstract

High-dose rate brachytherapy for prostate cancer has enjoyed rapid acceptance and is one of the most active areas of clinical research in the field. We present this chapter as a comprehensive technical analysis of rationale, methods, and outcomes including a substantive data review.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. D’Amico AV, Whittington R, Malkowicz SB et al (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95(2):281–286. doi:10.1002/cncr.10657

    Article  PubMed  Google Scholar 

  2. D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974

    Article  PubMed  Google Scholar 

  3. Kupelian P, Meyer JL (2011) Image-guided, adaptive radiotherapy of prostate cancer: toward new standards of radiotherapy practice. Front Radiat Ther Oncol 43:344–368. doi:10.1159/000322485

    Article  PubMed  Google Scholar 

  4. Kuban D, Tucker S, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74. doi:10.1016/j.ijrobp.2007.06.054

    Article  PubMed  Google Scholar 

  5. Zelefsky MJ, Yamada Y, Fuks Z et al (2008) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71(4):1028–1033. doi:10.1016/j.ijrobp.2007.11.066

    Article  PubMed  Google Scholar 

  6. Potters L, Morgenstern C, Calugaru E et al (2005) 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173(5):1562–1566. doi:10.1097/01.ju.0000154633.73092.8e

    Article  PubMed  Google Scholar 

  7. Zelefsky MJ, Kuban DA, Levy LB et al (2007) Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67(2):327–333. doi:10.1016/j.ijrobp.2006.08.056

    Article  PubMed  Google Scholar 

  8. Battermann JJ, Boon TA, Moerland MA (2004) Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 71(1):23–28. doi:10.1016/j.radonc.2004.01.020

    Article  PubMed  Google Scholar 

  9. Zamboglou N, Tselis N, Baltas D et al (2012) High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2012.07.004

    PubMed  Google Scholar 

  10. Demanes DJ, Martinez AA, Ghilezan M et al (2011) High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 81(5):1286–1292. doi:10.1016/j.ijrobp.2010.10.015

    Article  PubMed  Google Scholar 

  11. Hoskin P, Rojas A, Lowe G et al (2012) High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 82(4):1376–1384. doi:10.1016/j.ijrobp.2011.04.031

    Article  PubMed  Google Scholar 

  12. Galalae RM, Martinez A, Mate T et al (2004) Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58(4):1048–1055. doi:10.1016/j.ijrobp.2003.08.003

    Article  PubMed  Google Scholar 

  13. Pistis F, Guedea F, Pera J et al (2010) External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy 9(1):15–22. doi:10.1016/j.brachy.2009.05.001

    Article  PubMed  Google Scholar 

  14. Kotecha R, Yamada Y, Pei X et al (2013) Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 12(1):44–49. doi:10.1016/j.brachy.2012.05.003

    Article  PubMed  Google Scholar 

  15. Prada PJ, Mendez L, Fernández J et al (2012) Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol 7:31. doi:10.1186/1748-717X-7-31

    Article  PubMed  PubMed Central  Google Scholar 

  16. Deutsch I, Zelefsky MJ, Zhang Z et al (2010) Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 9(4):313–318. doi:10.1016/j.brachy.2010.02.196

    Article  PubMed  Google Scholar 

  17. Martinez AA, Gustafson G, Gonzalez J et al (2002) Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53(2):316–327

    Article  PubMed  Google Scholar 

  18. Demanes DJ, Rodriguez RR, Schour L et al (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61(5):1306–1316. doi:10.1016/j.ijrobp.2004.08.014

    Article  PubMed  Google Scholar 

  19. Milickovic N, Mavroidis P, Tselis N et al (2011) 4-D analysis of influence of patient movement and anatomy alteration on the quality of 3D U/S-based prostate HDR brachytherapy treatment delivery. Med Phys 38(9):4982–4993. doi:10.1118/1.3618735

    Article  PubMed  Google Scholar 

  20. Demanes DJ, Ghilezan MI (2014) High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy 13(6):529–541. doi:10.1016/j.brachy.2014.03.002

    Article  PubMed  Google Scholar 

  21. Morton GC, Hoskin PJ (2013) Brachytherapy: current status and future strategies – can high dose rate replace low dose rate and external beam radiotherapy? Clin Oncol (R Coll Radiol) 25(8):474–482. doi:10.1016/j.clon.2013.04.009

    Article  CAS  Google Scholar 

  22. Yoshioka Y, Yoshida K, Yamazaki H et al (2013) The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer. J Radiat Res 54(5):781–788. doi:10.1093/jrr/rrt027

    Article  PubMed  PubMed Central  Google Scholar 

  23. Challapalli A, Jones E, Harvey C et al (2012) High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. Br J Radiol 85 Spec No 1:S18–S27. doi:10.1259/bjr/15403217

    Google Scholar 

  24. Kupelian PA, Ciezki J, Reddy CA et al (2008) Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 71(1):16–22. doi:10.1016/j.ijrobp.2007.09.020

    Article  PubMed  Google Scholar 

  25. Kim MM, Hoffman KE, Levy LB et al (2012) Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer 48(11):1664–1671. doi:10.1016/j.ejca.2012.01.026

    Article  PubMed  Google Scholar 

  26. Zelefsky MJ, Reuter VE, Fuks Z et al (2008) Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179(4):1368–1373. doi:10.1016/j.juro.2007.11.063; discussion 1373

    Article  PubMed  PubMed Central  Google Scholar 

  27. Zelefsky MJ, Pei X, Chou JF et al (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60(6):1133–1139. doi:10.1016/j.eururo.2011.08.029

    Article  PubMed  Google Scholar 

  28. Nguyen Q, Levy LB, Lee AK et al (2013) Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer 119(18):3265–3271. doi:10.1002/cncr.28213

    Article  CAS  PubMed  Google Scholar 

  29. Pahlajani N, Ruth KJ, Buyyounouski MK et al (2012) Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 82(5):1949–1956. doi:10.1016/j.ijrobp.2011.04.005

    Article  PubMed  Google Scholar 

  30. Brenner DJ, Martinez AA, Edmundson GK et al (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52(1):6–13

    Article  PubMed  Google Scholar 

  31. Nath R, Bice WS, Butler WM et al (2009) AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137. Med Phys 36(11):5310–5322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ritter M, Forman J, Kupelian P et al (2009) Hypofractionation for prostate cancer. Cancer J 15(1):1–6. doi:10.1097/PPO.0b013e3181976614

    Article  PubMed  PubMed Central  Google Scholar 

  33. Edmundson GK, Yan D, Martinez AA (1995) Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy. Int J Radiat Oncol Biol Phys 33(5):1257–1263. doi:10.1016/0360-3016(95)00276-6

    Article  CAS  PubMed  Google Scholar 

  34. White EC, Kamrava MR, Demarco J et al (2013) High-dose-rate prostate brachytherapy consistently results in high quality dosimetry. Int J Radiat Oncol Biol Phys 85(2):543–548. doi:10.1016/j.ijrobp.2012.03.035

    Article  PubMed  Google Scholar 

  35. Mavroidis P, Katsilieri Z, Kefala V et al (2010) Radiobiological evaluation of the influence of dwell time modulation restriction in HIPO optimized HDR prostate brachytherapy implants. J Contemp Brachyther 2(3):117–128. doi:10.5114/jcb.2010.16923

    Article  Google Scholar 

  36. Karabis A, Giannouli S, Baltas D (2005) HIPO: A hybrid inverse treatment planning optimization algorithm in HDR brachytherapy. Radiother Oncol 76(Suppl 2):29

    Article  Google Scholar 

  37. Kono Y, Kubota K, Aruga T et al (2010) Swelling of the prostate gland by permanent brachytherapy may affect seed migration. Jpn J Clin Oncol 40(12):1159–1165. doi:10.1093/jjco/hyq118

    Article  PubMed  Google Scholar 

  38. Knaup C, Mavroidis P, Esquivel C et al (2012) Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med Phys 39(6):3291–3298. doi:10.1118/1.4712227

    Article  PubMed  PubMed Central  Google Scholar 

  39. Franca CAS, Vieira SL, Carvalho ACP et al (2009) Radioactive seed migration after prostate brachytherapy with iodine-125 using loose seeds versus stranded seeds. Int Braz J Urol 35(5):573–579; discussion 579–580

    Article  PubMed  Google Scholar 

  40. Shah AP, Kupelian PA, Willoughby TR et al (2011) An evaluation of intrafraction motion of the prostate in the prone and supine positions using electromagnetic tracking. Radiother Oncol 99(1):37–43. doi:10.1016/j.radonc.2011.02.012

    Article  PubMed  Google Scholar 

  41. Algan O, Jamgade A, Ali I et al (2012) The dosimetric impact of daily setup error on target volumes and surrounding normal tissue in the treatment of prostate cancer with intensity-modulated radiation therapy. Med Dosim 37(4):406–411. doi:10.1016/j.meddos.2012.03.003

    Article  PubMed  Google Scholar 

  42. Mutanga TF, de Boer HCJ, Rajan V et al (2012) Day-to-day reproducibility of prostate intrafraction motion assessed by multiple kV and MV imaging of implanted markers during treatment. Int J Radiat Oncol Biol Phys 83(1):400–407. doi:10.1016/j.ijrobp.2011.05.049

    Article  PubMed  Google Scholar 

  43. Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021–1031

    Article  CAS  PubMed  Google Scholar 

  44. Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101

    Article  CAS  PubMed  Google Scholar 

  45. Brenner DJ (2004) Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60(4):1013–1015. doi:10.1016/j.ijrobp.2004.04.014

    Article  PubMed  Google Scholar 

  46. Tucker SL, Thames HD, Michalski JM et al (2011) Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys 81(2):600–605. doi:10.1016/j.ijrobp.2010.11.080

    Article  PubMed  PubMed Central  Google Scholar 

  47. Miralbell R, Roberts SA, Zubizarreta E et al (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):e17–e24. doi:10.1016/j.ijrobp.2010.10.075

    Article  PubMed  Google Scholar 

  48. Lee WR (2009) Extreme hypofractionation for prostate cancer. Expert Rev Anticancer Ther 9(1):61–65. doi:10.1586/14737140.9.1.61

    Article  CAS  PubMed  Google Scholar 

  49. Bentzen SM, Dörr W, Gahbauer R et al (2012) Bioeffect modelling and equieffective dose concepts in radiation oncology--terminology, quantities and units. Radiother Oncol 105(2):266–268. doi:10.1016/j.radonc.2012.10.006

    Article  PubMed  Google Scholar 

  50. Fatyga M, Williamson JF, Dogan N et al (2009) A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modelling study. Med Phys 36(9):3995–4006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Masson S, Persad R, Bahl A (2012) HDR Brachytherapy in the Management of High-Risk Prostate Cancer. Adv Urol 980841. doi:10.1155/2012/980841

    Google Scholar 

  52. Bolla M, Poppel HV (2012) Management of prostate cancer. A multidisciplinary approach. Springer, Berlin/New York

    Book  Google Scholar 

  53. Hoskin P (2008) High dose rate brachytherapy for prostate cancer. Cancer Radiother 12(6-7):512–514. doi:10.1016/j.canrad.2008.07.012

    Article  CAS  PubMed  Google Scholar 

  54. Martinez AA, Gonzalez J, Ye H et al (2011) Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 79(2):363–370. doi:10.1016/j.ijrobp.2009.10.035

    Article  PubMed  Google Scholar 

  55. Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. High dose rate brachytherapy boost for prostate cancer: a systematic review.Cancer Treat Rev. 2014;40(3):414–425. doi:10.1016/j.ctrv.2013.10.006

    Google Scholar 

  56. Yoshioka Y, Konishi K, Suzuki O et al (2014) Monotherapeutic high-dose-rate brachytherapy for prostate cancer: a dose reduction trial. Radiother Oncol 110(1):114–119. doi:10.1016/j.radonc.2013.10.015

    Article  PubMed  Google Scholar 

  57. Yamada Y, Rogers L, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11(1):20–32. doi:10.1016/j.brachy.2011.09.008

    Article  PubMed  Google Scholar 

  58. Hoskin PJ, Colombo A, Henry A et al (2013) GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 107(3):325–332. doi:10.1016/j.radonc.2013.05.002

    Article  PubMed  Google Scholar 

  59. Mohler JL, Kantoff PW, Armstrong AJ et al (2013) Prostate cancer, version 1.2014. J Natl Compr Canc Netw 11(12):1471–1479

    CAS  PubMed  Google Scholar 

  60. Zelefsky MJ, Leibel SA, Gaudin PB et al (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41(3):491–500

    Article  CAS  PubMed  Google Scholar 

  61. Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8(2):162–200

    CAS  PubMed  Google Scholar 

  62. Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71. doi:10.1016/j.eururo.2010.10.039

    Article  PubMed  Google Scholar 

  63. Touijer K, Fuenzalida RP, Rabbani F et al (2011) Extending the indications and anatomical limits of pelvic lymph node dissection for prostate cancer: Improved staging or increased morbidity? BJU Int 108(3):372–377. doi:10.1111/j.1464-410X.2010.09877

    Article  PubMed  Google Scholar 

  64. Evangelista L, Guttilla A, Zattoni F et al (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048. doi:10.1016/j.eururo.2012.09.039

    Article  PubMed  Google Scholar 

  65. Maurer T, Eiber M, Krause BJ (2014) Molekulare multimodale Hybridbildgebung des Prostata- und Blasenkarzinoms (Molecular multimodal hybrid imaging in prostate and bladder cancer). Urol A 53(4):469–483. doi:10.1007/s00120-014-3440-5

    Article  CAS  Google Scholar 

  66. Eid K, Krughoff K, Stoimenova D et al (2013) Validation of the urgency, weak stream, incomplete emptying, and nocturia (UWIN) score compared with the american urological association symptoms score in assessing lower urinary tract symptoms in the clinical setting. Urology 83:181–185. doi:10.1016/j.urology.2013.08.039

    Article  PubMed  Google Scholar 

  67. Le H, Rojas A, Alonzi R et al (2013) The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer. Int J Radiat Oncol Biol Phys 87(2):270–274. doi:10.1016/j.ijrobp.2013.05.022

    Article  PubMed  Google Scholar 

  68. Monroe AT, Faricy PO, Jennings SB et al (2008) High-dose-rate brachytherapy for large prostate volumes (≥50cc)—uncompromised dosimetric coverage and acceptable toxicity. Brachytherapy 7(1):7–11. doi:10.1016/j.brachy.2007.10.005

    Article  PubMed  Google Scholar 

  69. Rogers CL, Alder SC, Rogers RL et al (2012) High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 187(1):109–116. doi:10.1016/j.juro.2011.09.050

    Article  PubMed  Google Scholar 

  70. Yamada Y, Bhatia S, Zaider M et al (2006) Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 5(3):157–164. doi:10.1016/j.brachy.2006.03.004

    Article  PubMed  Google Scholar 

  71. Ishiyama H, Hirayama T, Jhaveri P et al (2012) Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review. Am J Clin Oncol. doi:10.1097/COC.0b013e3182546821

    Google Scholar 

  72. Luo HL, Fang FM, Chuang YC et al (2009) Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer. BJU Int 104(11):1620–1623. doi:10.1111/j.1464-410X.2009.08664.x

    Article  PubMed  Google Scholar 

  73. Luo HL, Fang FM, Kang CH et al (2013) Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate? Int Urol Nephrol 45(1):113–119. doi:10.1007/s11255-012-0277-y

    Article  PubMed  Google Scholar 

  74. Peddada AV, Jennings SB, Faricy PO et al (2007) Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection. J Urol 178(5):1963–1967. doi:10.1016/j.juro.2007.07.028

    Article  PubMed  Google Scholar 

  75. Sakamoto N, Akitake M, Ikoma S et al (2011) Clinical outcome in prostate cancer patients undergoing high-dose-rate brachytherapy with external beam radiotherapy in our institute. Nippon Hinyokika Gakkai Zasshi 102(4):621–627

    PubMed  Google Scholar 

  76. Yoshioka Y, Konishi K, Sumida I et al (2011) Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 80(2):469–475. doi:10.1016/j.ijrobp.2010.02.013

    Article  PubMed  Google Scholar 

  77. Lakosi F, Antal G, Vandulek C et al (2011) Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy. Pathol Oncol Res 17(2):315–324. doi:10.1007/s12253-010-9319-x

    Article  PubMed  Google Scholar 

  78. Ménard C, Susil RC, Choyke P et al (2004) MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys 59(5):1414–1423. doi:10.1016/j.ijrobp.2004.01.016

    Article  PubMed  PubMed Central  Google Scholar 

  79. Martin T, Röddiger S, Kurek R et al (2004) 3-D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol 71(1):35–41. doi:10.1016/j.radonc.2003.10.004

    Article  PubMed  Google Scholar 

  80. Ghilezan M, Martinez A, Gustason G et al (2011) High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2011.05.001

    Google Scholar 

  81. Galalae RM, Kovács G, Schultze J et al (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52(1):81–90

    Article  PubMed  Google Scholar 

  82. Hoskin PJ, Motohashi K, Bownes P et al (2007) High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 84(2):114–120. doi:10.1016/j.radonc.2007.04.011

    Article  PubMed  Google Scholar 

  83. Martin T, Kolotas C, Dannenberg T et al (1999) New interstitial HDR brachytherapy technique for prostate cancer: CT based 3D planning after transrectal implantation. Radiother Oncol 52(3):257–260

    Article  CAS  PubMed  Google Scholar 

  84. Anderson ES, Margolis DJA, Mesko S et al (2014) Multiparametric MRI identifies and stratifies prostate cancer lesions: implications for targeting intraprostatic targets. Brachytherapy 13(3):292–298. doi:10.1016/j.brachy.2014.01.011

    Article  PubMed  Google Scholar 

  85. Boonsirikamchai P, Choi S, Frank SJ et al (2013) MR imaging of prostate cancer in radiation oncology: what radiologists need to know. Radiographics 33(3):741–761. doi:10.1148/rg.333125041

    Article  PubMed  Google Scholar 

  86. Diamantopoulos S, Milickovic N, Butt S et al (2011) Effect of using different U/S probe Standoff materials in image geometry for interventional procedures: the example of prostate. J Contemp Brachytherapy 3(4):209–219. doi:10.5114/jcb.2011.26472

    Article  PubMed  PubMed Central  Google Scholar 

  87. Nath R, Anderson LL, Luxton G et al (1995) Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 22(2):209–234

    Article  CAS  PubMed  Google Scholar 

  88. Perez-Calatayud J, Ballester F, Das RK et al (2012) Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: report of the AAPM and ESTRO. Med Phys 39(5):2904–2929. doi:10.1118/1.3703892

    Article  PubMed  Google Scholar 

  89. Dinkla AM, Pieters BR, Koedooder K et al (2013) Improved tumour control probability with MRI-based prostate brachytherapy treatment planning. Acta Oncol 52(3):658–665. doi:10.3109/0284186X.2012.744875

    Article  PubMed  Google Scholar 

  90. Tanaka H, Hayashi S, Ohtakara K et al (2011) Usefulness of CT-MRI fusion in radiotherapy planning for localized prostate cancer. J Radiat Res 52(6):782–788

    Article  PubMed  Google Scholar 

  91. Tzikas A, Karaiskos P, Papanikolaou N et al (2011) Investigating the clinical aspects of using CT vs. CT-MRI images during organ delineation and treatment planning in prostate cancer radiotherapy. Technol Cancer Res Treat 10(3):231–242

    CAS  PubMed  Google Scholar 

  92. Holly R, Morton GC, Sankreacha R et al (2011) Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy. Brachytherapy 10(4):299–305. doi:10.1016/j.brachy.2010.11.007

    Article  PubMed  Google Scholar 

  93. Seppenwoolde Y, Kolkman-Deurloo I, Sipkema D et al (2008) HDR prostate monotherapy: dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. Radiother Oncol 86(1):114–119. doi:10.1016/j.radonc.2007.11.004

    Article  PubMed  Google Scholar 

  94. Whitaker M, Hruby G, Lovett A et al (2011) Prostate HDR brachytherapy catheter displacement between planning and treatment delivery. Radiother Oncol 101(3):490–494. doi:10.1016/j.radonc.2011.08.004

    Article  PubMed  Google Scholar 

  95. Baltas D, Zamboglou N, Sakelliou L (2007) The physics of modern brachytherapy for oncology. Series in medical physics and biomedical engineering. Taylor & Francis, Boca Raton

    Google Scholar 

  96. Chavaudra J, Bridier A (2001) Définition des volumes en radiothérapie externe: rapports ICRU 50 et 62 (Definition of volumes in external radiotherapy: ICRU reports 50 and 62). Cancer Radiother 5(5):472–478

    Article  CAS  PubMed  Google Scholar 

  97. Purdy JA (2004) Current ICRU definitions of volumes: limitations and future directions. Semin Radiat Oncol 14(1):27–40. doi:10.1053/j.semradonc.2003.12.002

    Article  PubMed  Google Scholar 

  98. Borghede G, Hedelin H, Holmäng S et al (1997) Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland. Radiother Oncol 44(3):245–250

    Article  CAS  PubMed  Google Scholar 

  99. Deger S, Boehmer D, Roigas J et al (2005) High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 47(4):441–448. doi:10.1016/j.eururo.2004.11.014

    Article  PubMed  Google Scholar 

  100. Hoskin P, Rojas A, Ostler P et al (2014) High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity. Radiother Oncol 110(2):268–271. doi:10.1016/j.radonc.2013.09.025

    Article  PubMed  Google Scholar 

  101. Kim Y, Hsu IJ, Lessard E et al (2004) Dose uncertainty due to computed tomography (CT) slice thickness in CT-based high dose rate brachytherapy of the prostate cancer. Med Phys 31(9):2543–2548

    Article  PubMed  Google Scholar 

  102. Zheng D, Todor DA (2011) A novel method for accurate needle-tip identification in trans-rectal ultrasound-based high-dose-rate prostate brachytherapy. Brachytherapy 10(6):466–473. doi:10.1016/j.brachy.2011.02.214

    Article  PubMed  Google Scholar 

  103. Panettieri V, Smith RL, Mason NJ et al (2014) Comparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy. J Appl Clin Med Phys 15(6):5055

    PubMed  Google Scholar 

  104. Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487. doi:10.1016/S1470-2045(07)70143-2

    Article  PubMed  Google Scholar 

  105. Peeters STH, Heemsbergen WD, Koper PCM et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–1996. doi:10.1200/JCO.2005.05.2530

    Article  PubMed  Google Scholar 

  106. Pollack A, Zagars GK, Starkschall G (2002) et al; Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–1105

    Article  PubMed  Google Scholar 

  107. Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28(7):1106–1111. doi:10.1200/JCO.2009.25.8475

    Article  PubMed  PubMed Central  Google Scholar 

  108. Hermesse J, Biver S, Jansen N et al (2009) A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy. Strahlenther Onkol 185(11):736–742. doi:10.1007/s00066-009-2009-5

    Article  PubMed  Google Scholar 

  109. Hermesse J, Biver S, Jansen N et al (2010) Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate. Int J Radiat Oncol Biol Phys 76(1):269–276. doi:10.1016/j.ijrobp.2009.05.046

    Article  PubMed  Google Scholar 

  110. Hsu IC, Pickett B, Shinohara K et al (2000) Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation. Int J Radiat Oncol Biol Phys 46(4):851–858

    Article  CAS  PubMed  Google Scholar 

  111. Pieters BR, van de Kamer JB, van Herten YRJ et al (2008) Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 88(1):46–52. doi:10.1016/j.radonc.2008.02.023

    Article  PubMed  Google Scholar 

  112. Sathya JR, Davis IR, Julian JA et al (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23(6):1192–1199. doi:10.1200/JCO.2005.06.154

    Article  PubMed  Google Scholar 

  113. Aström L, Pedersen D, Mercke C et al (2005) Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 74(2):157–161. doi:10.1016/j.radonc.2004.10.014

    Article  PubMed  Google Scholar 

  114. Noda Y, Sato M, Shirai S et al (2011) Efficacy and safety of high-dose-rate brachytherapy of single implant with two fractions combined with external beam radiotherapy for hormone-naïve localized prostate cancer. Cancers (Basel) 3(3):3585–3600. doi:10.3390/cancers3033585

    Article  Google Scholar 

  115. Morton GC, Loblaw DA, Sankreacha R et al (2010) Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 77(3):811–817. doi:10.1016/j.ijrobp.2009.05.054

    Article  PubMed  Google Scholar 

  116. Agoston P, Major T, Fröhlich G et al (2011) Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. Brachytherapy 10(5):376–384. doi:10.1016/j.brachy.2011.01.003

    Article  PubMed  Google Scholar 

  117. Hiratsuka J, Jo Y, Yoshida K et al (2004) Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59(3):684–690. doi:10.1016/j.ijrobp.2003.11.035

    Article  PubMed  Google Scholar 

  118. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Int J Radiat Oncol Biol Phys 37(5):1035–1041

    Google Scholar 

  119. Pellizzon ACA, Salvajoli J, Novaes P et al (2008) The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 5(3):113–120

    Article  PubMed  PubMed Central  Google Scholar 

  120. Phan TP, Syed AMN, Puthawala A et al (2007) High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 177(1):123–127. doi:10.1016/j.juro.2006.08.109; discussion 127

    Article  PubMed  Google Scholar 

  121. Viani GA, Pellizzon AC, Guimarães FS et al (2009) High dose rate and external beam radiotherapy in locally advanced prostate cancer. Am J Clin Oncol 32(2):187–190. doi:10.1097/COC.0b013e3181841f78

    Article  PubMed  Google Scholar 

  122. Roach M, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974. doi:10.1016/j.ijrobp.2006.04.029

    Article  PubMed  Google Scholar 

  123. Galalae RM, Martinez A, Nuernberg N et al (2006) Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkol 182(3):135–141. doi:10.1007/s00066-006-1448-5

    Article  PubMed  Google Scholar 

  124. Izard MA, Haddad RL, Fogarty GB et al (2006) Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192) Ir source, and neoadjuvant hormonal manipulation for prostate cancer. Int J Radiat Oncol Biol Phys 66(1):38–47. doi:10.1016/j.ijrobp.2006.04.002

    Article  PubMed  Google Scholar 

  125. Martinez A, Gonzalez J, Spencer W et al (2003) Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169(3):974–979. doi:10.1097/01.ju.0000052720.62999.a9; discussion 979–980

    Article  PubMed  Google Scholar 

  126. Martinez AA, Demanes DJ, Galalae R et al (2005) Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 62(5):1322–1331. doi:10.1016/j.ijrobp.2004.12.053

    Article  PubMed  Google Scholar 

  127. Vargas CE, Martinez AA, Boike TP et al (2006) High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys 66(2):416–423. doi:10.1016/j.ijrobp.2006.04.045

    Article  PubMed  Google Scholar 

  128. de Meerleer G, Vakaet L, Meersschout S et al (2004) Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60(3):777–787. doi:10.1016/j.ijrobp.2004.04.017

    Article  PubMed  Google Scholar 

  129. Liauw SL, Weichselbaum RR, Rash C et al (2009) Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat 8(3):201–206

    Article  CAS  PubMed  Google Scholar 

  130. Lips IM, Dehnad H, van Gils CH et al (2008) High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 3:15. doi:10.1186/1748-717X-3-15

    Article  PubMed  PubMed Central  Google Scholar 

  131. Martinez AA, Kestin LL, Stromberg JS et al (2000) Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. Int J Radiat Oncol Biol Phys 47(2):343–352

    Article  CAS  PubMed  Google Scholar 

  132. Martinez AA, Pataki I, Edmundson G et al (2001) Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49(1):61–69

    Article  CAS  PubMed  Google Scholar 

  133. Rodriguez RR, Demanes DJ, Altieri GA (1999) High dose rate brachytherapy in the treatment of prostate cancer. Hematol Oncol Clin North Am 13(3):503–523

    Article  CAS  PubMed  Google Scholar 

  134. Yoshioka Y, Nose T, Yoshida K et al (2000) High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 48(3):675–681

    Article  CAS  PubMed  Google Scholar 

  135. Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, See A, Duchesne GM. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat Oncol Biol Phys. 2012;82(5):1889–1896. doi:10.1016/j.ijrobp.2010.09.006

    Google Scholar 

  136. Corner C, Rojas AM, Bryant L et al (2008) A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 72(2):441–446. doi:10.1016/j.ijrobp.2007.12.026

    Article  PubMed  Google Scholar 

  137. Ghadjar P, Keller T, Rentsch CA et al (2009) Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 8(1):45–51. doi:10.1016/j.brachy.2008.09.004

    Article  PubMed  Google Scholar 

  138. Grills IS, Martinez AA, Hollander M et al (2004) High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171(3):1098–1104. doi:10.1097/01.ju.0000113299.34404.22

    Article  PubMed  Google Scholar 

  139. Komiya A, Fujiuchi Y, Ito T et al (2013) Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy. Int J Urol 20(2):185–192. doi:10.1111/j.1442-2042.2012.03125.x

    Article  CAS  PubMed  Google Scholar 

  140. Kukiełka AM, Dąbrowski T, Walasek T, Olchawa A, Kudzia R, Dybek D. High-dose-rate brachytherapy as a monotherapy for prostate cancer–Single-institution results of the extreme fractionation regimen. Brachytherapy. 2015;14(3):359–365. doi:10.1016/j.brachy.2015.01.004

    Google Scholar 

  141. Mark R, Anderson P, Akins R (2010) Interstitial high-dose-rate brachytherapy as monotherapy for early stage prostate cancer: Median 8-year results in 301 patients. (Abstract). Brachytherapy 9:76

    Article  Google Scholar 

  142. Martin T, Baltas D, Kurek R et al (2004) 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 180(4):225–232. doi:10.1007/s00066-004-1215-4

    Article  PubMed  Google Scholar 

  143. Martinez AA, Demanes J, Vargas C et al (2010) High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33(5):481–488. doi:10.1097/COC.0b013e3181b9cd2f

    Article  PubMed  Google Scholar 

  144. Prada PJ, Jimenez I, González-Suárez H et al (2012) High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy 11(2):105–110. doi:10.1016/j.brachy.2011.05.003

    Article  PubMed  Google Scholar 

  145. Díez P, Mullassery V, Dankulchai P et al (2014) Dosimetric analysis of urethral strictures following HDR (192)Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer. Radiother Oncol 113(3):410–413. doi:10.1016/j.radonc.2014.10.007

    Article  PubMed  Google Scholar 

  146. Tselis N, Tunn UW, Chatzikonstantinou G et al (2013) High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients. Radiat Oncol 8:115. doi:10.1186/1748-717X-8-115

    Article  PubMed  PubMed Central  Google Scholar 

  147. Ghadjar P, Oesch SL, Rentsch CA et al (2014) Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Radiat Oncol 9:122. doi:10.1186/1748-717X-9-122

    Article  PubMed  PubMed Central  Google Scholar 

  148. Vargas C, Ghilezan M, HOLLANDER M et al (2005) A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol 174(3):882–887. doi:10.1097/01.ju.0000169136.55891.21

    Article  PubMed  Google Scholar 

  149. el Din KE, Koch WF, Wildt MJ et al (1996) Reliability of the International Prostate Symptom Score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia. J Urol 155(6):1959–1964

    Article  PubMed  Google Scholar 

  150. Rosen RC, Allen KR, Ni X et al (2011) Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol 60(5):1010–1016. doi:10.1016/j.eururo.2011.07.053

    Article  PubMed  Google Scholar 

  151. Stone NN, Potters L (2007) Davis BJ et al: Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 9(5):1472–1477. doi:10.1016/j.ijrobp.2007.05.002

    Article  Google Scholar 

  152. Stone NN, Stock RG, Cesaretti JA et al (2010) Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76(2):355–360. doi:10.1016/j.ijrobp.2009.01.078

    Article  PubMed  Google Scholar 

  153. Krauss D, Kestin L, Ye H et al (2011) Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 80(4):1064–1071. doi:10.1016/j.ijrobp.2010.04.004

    Article  PubMed  Google Scholar 

  154. Freeman DE, King CR (2011) Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 6:3. doi:10.1186/1748-717X-6-3

    Article  PubMed  PubMed Central  Google Scholar 

  155. King CR, Brooks JD, Gill H et al (2009) Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73(4):1043–1048. doi:10.1016/j.ijrobp.2008.05.059

    Article  PubMed  Google Scholar 

  156. King CR, Brooks JD, Gill H et al (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82(2):877–882. doi:10.1016/j.ijrobp.2010.11.054

    Article  PubMed  Google Scholar 

  157. McBride SM, Wong DS, Dombrowski JJ et al (2012) Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 118(15):3681–3690. doi:10.1002/cncr.26699

    Article  PubMed  Google Scholar 

  158. Teh BS, Ishiyama H, Mathews T et al (2010) Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. Discov Med 10(52):255–262

    PubMed  Google Scholar 

  159. Fuller DB, Naitoh J, Mardirossian G (2014) Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations. Front Oncol 4:321. doi:10.3389/fonc.2014.00321

    PubMed  PubMed Central  Google Scholar 

  160. Spratt DE, Scala LM, Folkert M et al (2013) A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. Brachytherapy 12(5):428–433. doi:10.1016/j.brachy.2013.03.003

    Article  PubMed  Google Scholar 

  161. Fuller DB, Naitoh J, Lee C et al (2008) Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70(5):1588–1597. doi:10.1016/j.ijrobp.2007.11.067

    Article  PubMed  Google Scholar 

  162. Aluwini S, van Rooij P, Hoogeman M et al (2010) CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol 24(5):865–869. doi:10.1089/end.2009.0438

    Article  PubMed  Google Scholar 

  163. Bruce JY, Lang JM, McNeel DG et al (2012) Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol 10(11):716–722

    PubMed  Google Scholar 

  164. Ahmed HU, Pendse D, Illing R et al (2007) Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 4(11):632–642. doi:10.1038/ncponc0959

    Article  PubMed  Google Scholar 

  165. Chen CP, Weinberg V, Shinohara K et al (2013) Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 86(2):324–329. doi:10.1016/j.ijrobp.2013.01.027

    Article  PubMed  Google Scholar 

  166. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597

    Article  CAS  PubMed  Google Scholar 

  167. Ward JF, Pagliaro LC, Pisters LL (2008) Salvage therapy for radio-recurrent prostate cancer. Curr Probl Cancer 32(6):242–271. doi:10.1016/j.currproblcancer.2008.10.001

    Article  PubMed  Google Scholar 

  168. Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67(4):1106–1112. doi:10.1016/j.ijrobp.2006.10.012

    Article  PubMed  Google Scholar 

  169. Oliai C, Yang L, Lee JY (2013) Prospective quality of life and efficacy of high-dose-rate brachytherapy salvage for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 87(2):S396

    Article  Google Scholar 

  170. Pellizzon A, Miziara MC. Neviani C, Miziara R (2009) Long-term results of salvage interstitial high-dose brachytherapy for local-only recurrent prostate cancer treated with definitive conventional external beam radiotherapy. ASCO abstract 2009. http://meetinglibrary.asco.org/content/20049-64

  171. Scala L, Page PN, Lee JW (2009) Salvage high dose rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy. Int J Radiat Oncol Biol Phys 75(3):S322

    Article  Google Scholar 

  172. Tharp M, Hardacre M, Bennett R et al (2008) Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 7(3):231–236. doi:10.1016/j.brachy.2008.03.003

    Article  PubMed  Google Scholar 

  173. Yamada Y, Kollmeier MA, Pei X et al (2014) A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy 13(2):111–116. doi:10.1016/j.brachy.2013.11.005

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology and Interdisciplinary Oncology, Sana Klinikum, Offenbach, Germany

    Nikolaos Tselis MD, PhD & Nikolaos Zamboglou MD, PhD

  2. Department of Medical Physics and Engineering, Sana Klinikum, Offenbach, Germany

    Dimos Baltas PhD

Authors
  1. Nikolaos Tselis MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimos Baltas PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nikolaos Zamboglou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikolaos Tselis MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA

    Paolo Montemaggi

  2. AlleghenyHealthNetworkCancer Ins,Divi RO, Drexel Univ, College of Medi, Pittsburgh, Pennsylvania, USA

    Mark Trombetta

  3. Dept Radiation Oncology, Drexel Univ, College of Medi, Philadelphia, Pennsylvania, USA

    Luther W. Brady

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Tselis, N., Baltas, D., Zamboglou, N. (2016). Prostate: High-Dose Rate Brachytherapy in the Treatment of Clinically Organ-Confined Prostate Cancer. In: Montemaggi, P., Trombetta, M., Brady, L. (eds) Brachytherapy. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/978-3-319-26791-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26791-3_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26789-0

  • Online ISBN: 978-3-319-26791-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation